+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AAV Gene Therapy Injection Market - Global Forecast 2025-2030- Product Image
AAV Gene Therapy Injection Market - Global Forecast 2025-2030- Product Image
Sale

AAV Gene Therapy Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6145861
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Adeno-associated virus (AAV) gene therapy injections are redefining the possibilities of personalized medicine, offering new levels of precision and durability in treating hereditary and acquired disorders. The AAV gene therapy injection market is characterized by rapid advances, robust collaboration, and significant investment, making it a focal point for healthcare leaders pursuing innovative solutions for rare and complex diseases.

Market Snapshot: AAV Gene Therapy Injection

The AAV gene therapy injection market has entered a phase of accelerated clinical and technology-driven growth. Recent advancements in vector engineering, manufacturing capabilities, and regulatory adaptation are transforming how therapeutic genes are delivered directly to patient tissues. Early clinical milestones in rare, genetic disorders have set a precedent for further breakthrough applications, capturing wide interest from pharmaceutical developers, healthcare systems, and regulatory bodies.

Scope & Segmentation

This report delivers a comprehensive analysis of the AAV gene therapy injection ecosystem, mapping key market segments and regional deployment channels. Industry stakeholders will find a structured view of core market dynamics, with clear coverage of technologies, end users, and geographies.

  • Indications: Hemophilia, Inherited Retinal Diseases, Lysosomal Storage Disorders (Fabry Disease, Gaucher Disease, Pompe Disease), Neurological Disorders (Parkinson’s Disease, Spinal Muscular Atrophy)
  • Vector Types: AAV2, AAV5, AAV8, AAV9
  • Delivery Methods: Intramuscular, Intrathecal, Intravenous
  • Distribution Channels: Direct Sales, Specialty Pharmacies
  • End Users: Hospitals, Research Institutes, Specialty Clinics
  • Regions & Sub-regions: Americas (United States – California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Novartis AG, Spark Therapeutics, Inc., BioMarin Pharmaceutical Inc., uniQure N.V., REGENXBIO Inc., Asklepios BioPharmaceutical, Inc., MeiraGTx Ltd., 4D Molecular Therapeutics, Inc., Voyager Therapeutics, Inc., Solid Biosciences Inc.

Key Takeaways

  • Next-generation capsids engineered for enhanced tissue specificity and safety are expanding clinical applications for AAV gene therapy injections across key therapeutic areas.
  • Manufacturing advances, including improved bioreactor design and process analytics, are reducing production bottlenecks and enabling clinical and eventual commercial scalability.
  • Adaptations in regulatory frameworks are accelerating approval pathways while maintaining high safety and efficacy standards, effectively supporting industry innovation.
  • Robust academic-industry partnerships are fostering deeper knowledge sharing, risk reduction in late-stage development, and diversified research pipelines targeting rare genetic conditions.
  • Integration of digital health solutions and patient-centric trial models is increasing diversity in study populations and ensuring stronger post-treatment monitoring.
  • Regional variances in funding, regulatory harmonization, and infrastructure require nuanced strategies for deployment and resource allocation to optimize global market impact.

Tariff Impact on AAV Gene Therapy Injection Supply Chains

Upcoming U.S. tariff policies are expected to influence supply chains by raising costs and extending lead times for imported components and reagents. In anticipation, developers are evaluating alternative suppliers, increasing domestic manufacturing, and collaborating through consortia to advocate for tariff relief on critical materials. Contract manufacturing partnerships are emerging as a strategy for supply continuity, enhancing resilience against policy-driven disruption while supporting scalable production environments.

Methodology & Data Sources

The findings in this report are derived from primary interviews with clinical and industry experts, including regulatory affairs leaders and manufacturing specialists. Secondary analysis incorporates peer-reviewed publications, patent filings, clinical trial registries, and regulatory documentation. Rigorous triangulation, peer review by subject matter experts, and continuous advisory feedback ensure a high degree of reliability and actionable insight.

Why This Report Matters

  • Enables informed decision-making by consolidating the latest trends, emerging risks, and growth opportunities in the AAV gene therapy injection market.
  • Provides a granular mapping of competitive landscapes, critical technologies, and key regulatory shifts that impact go-to-market strategies.
  • Equips senior stakeholders with practical guidance for investment, market entry, and partnership decisions across global markets.

Conclusion

The AAV gene therapy injection market is evolving through technological innovation, strategic partnerships, and adaptive supply chain frameworks. Stakeholders leveraging this report will gain the clarity needed to navigate the complexities of clinical and commercial development in this dynamic sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in AAV capsid engineering to improve tissue targeting and evade host immune responses
5.2. Optimization of manufacturing scale up processes to reduce costs and ensure commercial supply continuity
5.3. Emergence of novel immunomodulatory strategies to prevent neutralizing antibody formation against AAV vectors
5.4. Adoption of bioinformatics and AI tools to design optimized AAV vectors with enhanced transduction efficiency
5.5. Expansion of AAV gene therapy indications into neurological and retinal disorders through targeted delivery routes
5.6. Regulatory bodies exploring accelerated approval pathways and harmonized guidelines for AAV based therapies
5.7. Consolidation of intellectual property rights in AAV vector technology driving competitive barriers to entry
5.8. Strategic collaborations between biotech firms and pharmaceutical giants to expand AAV pipeline portfolios
5.9. Collection and analysis of long term real world data to assess safety profiles and durability of AAV therapies
5.10. Development of next generation AAV serotypes and engineered variants to overcome pre existing immunity challenges
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. AAV Gene Therapy Injection Market, by Indication
8.1. Introduction
8.2. Hemophilia
8.3. Inherited Retinal Disease
8.4. Lysosomal Storage Disorders
8.4.1. Fabry Disease
8.4.2. Gaucher Disease
8.4.3. Pompe Disease
8.5. Neurological Disorders
8.5.1. Parkinson’s Disease
8.5.2. Spinal Muscular Atrophy
9. AAV Gene Therapy Injection Market, by Vector Type
9.1. Introduction
9.2. AAV2
9.3. AAV5
9.4. AAV8
9.5. AAV9
10. AAV Gene Therapy Injection Market, by Delivery Method
10.1. Introduction
10.2. Intramuscular
10.3. Intrathecal
10.4. Intravenous
11. AAV Gene Therapy Injection Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Specialty Pharmacies
12. AAV Gene Therapy Injection Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Research Institutes
12.4. Specialty Clinics
13. Americas AAV Gene Therapy Injection Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa AAV Gene Therapy Injection Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific AAV Gene Therapy Injection Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Spark Therapeutics, Inc.
16.3.3. BioMarin Pharmaceutical Inc.
16.3.4. uniQure N.V.
16.3.5. REGENXBIO Inc.
16.3.6. Asklepios BioPharmaceutical, Inc.
16.3.7. MeiraGTx Ltd.
16.3.8. 4D Molecular Therapeutics, Inc.
16.3.9. Voyager Therapeutics, Inc.
16.3.10. Solid Biosciences Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AAV GENE THERAPY INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AAV GENE THERAPY INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AAV GENE THERAPY INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. AAV GENE THERAPY INJECTION MARKET: RESEARCHAI
FIGURE 26. AAV GENE THERAPY INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 27. AAV GENE THERAPY INJECTION MARKET: RESEARCHCONTACTS
FIGURE 28. AAV GENE THERAPY INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AAV GENE THERAPY INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INHERITED RETINAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INHERITED RETINAL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY FABRY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY FABRY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY POMPE DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV2, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV5, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV5, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV8, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY AAV9, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL AAV GENE THERAPY INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES AAV GENE THERAPY INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 100. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 101. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 102. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 103. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 106. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 107. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 120. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 121. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 186. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 187. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 188. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 189. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 190. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 191. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 192. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 193. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. GERMANY AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 202. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 203. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 204. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 205. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 206. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 207. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FRANCE AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 228. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 229. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 230. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 231. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 232. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 233. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 234. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 235. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ITALY AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 242. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 243. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 244. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 245. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 246. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 247. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 248. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 249. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SPAIN AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2018-2024 (USD MILLION)
TABLE 298. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, 2025-2030 (USD MILLION)
TABLE 299. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 300. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 301. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
TABLE 302. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY VECTOR TYPE, 2025-2030 (USD MILLION)
TABLE 303. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
TABLE 304. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
TABLE 305. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. DENMARK AAV GENE THERAPY INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. DENMARK AAV GENE THERA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this AAV Gene Therapy Injection market report include:
  • Novartis AG
  • Spark Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • uniQure N.V.
  • REGENXBIO Inc.
  • Asklepios BioPharmaceutical, Inc.
  • MeiraGTx Ltd.
  • 4D Molecular Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Solid Biosciences Inc.

Related Topics

Related Reports

Ophthalmic AAV Gene Therapy Market - Global Forecast 2025-2030 - Product Image

Ophthalmic AAV Gene Therapy Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
AAV Gene Therapy Drugs Market - Global Forecast 2025-2030 - Product Image

AAV Gene Therapy Drugs Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region - Product Image

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region

  • Report
  • 768 Pages
  • Global
From
Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2025 - Product Image

Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 400 Pages
  • Global
From
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2025 - Product Image

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.